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Abstract
Adult T-cell leukemia (ATL) was first reported as a distinct clinical entity in 1977 in Japan. The
predominant physical findings are skin lesions, lymphadenopathy and hepatosplenomegaly. The ATL
cells are of mature T-helper phenotype and have a characteristic appearance with indented nuclei.
There is striking frequent hypercalcemia with increased numbers of osteoclasts. Central to the
identification of the disease is a striking geographic clustering in southwestern Japan and the
isolation of human T-cell lymphotropic virus type-1 (HTLV-1) from the cell lines of patients.
Worldwide epidemiological studies have been made through international collaborations. Several
diseases were found to be related to HTLV-1 infection. Moreover, it was noted that an
immunodeficiency state may be induced by HTLV-1 infection. In Japan, HTLV-1 carriers have been
estimated to be 1.2 million, and more than 700 cases of ATL have been diagnosed each year.
Adult T-cell leukemia (ATL) was described as a distinct
clinical entity in 1977 in Kyoto, Japan [1,2]. The illness is
manifested by presentation in adult life: frequent skin
lesions, lymphadenopathy, hepatosplenomegaly, and ele-
vated white blood cell count with abnormal lymphoid
cells. The abnormal ATL cells are of mature T-helper phe-
notype and have a characteristic appearance with espe-
cially indented or lobulated nuclei. There is strikingly
frequent hypercalcemia with increased numbers of osteo-
clasts. Central to the identification of the syndrome is the
striking geographic clustering in southwestern Japan and
the isolation of the human T-cell lymphotropic virus type-
1 (HTLV-1) from the cell lines of patients with ATL.
Background of our ATL study
It was around the 1973 that we came to recognize the
existence of ATL, previously an unknown disease. I would
like to give a retrospective view concerning the back-
ground of our studies on ATL.
Many clinicians in Japan probably feel that the descrip-
tions of diseases in the literature from abroad differ from
the features of the diseases observed in their practices in
Japan. We can mention many examples in the field of
hematology. One of these is that the incidence of chronic
lymphocytic leukemia is quite low, being only 2% of all
hematological malignancies. What differs is not only the
incidence but also the detailed symptoms and signs of dis-
eases. This vague feeling that an autochthonous pathology
exists in Japan may be considered as key factor in the back-
ground of our study of ATL.
The second major factor is the recent progress made in
basic immunology. Having an interest in immunoglobu-
lin abnormalities, I studied multiple myeloma and related
diseases in the days when even the word 'immunoglobu-
lin' was not yet in use. The central theme of immunology
at that time was to identify the structure of antibodies.
Immunology has advanced rapidly, and myeloma was
defined as a B-cell malignancy. Therefore, it was quite nat-
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ural to enlarge the objectives of our clinical studies to all
lymphoproliferative diseases.
At this stage of our research in Kyoto, joint studies with
young researchers were initiated. This was the third and
most important element of the background of our ATL
study. I became acquainted with Drs. Takashi Uchiyama
and Junji Yodoi, who are currently both working in Kyoto,
during their postgraduate training. Dr. Yodoi prepared an
antiserum against human thymocytes and invited us to
direct our attention to T-cells.
In the course of examining patients with various lympho-
proliferative disorders, we arrived at the conclusion that
ATL was a disease which had not been described anywhere
before. It was recognized that T-cell malignancy had a rel-
atively high incidence among Japanese adults and that
most of the patients with this disease were from Kyushu.
This discovery was made from our bedside observations
rather than from laboratory work. Thereafter, Dr. Uchi-
yama went to the National Cancer Institute, Bethesda to
work with Dr. Thomas A. Waldmann and raised a mono-
clonal antibody, called 'Tac' antibody, which later played
an important role in our ATL studies. Dr. Yodoi has devel-
oped a new field of research by identifying a novel
cytokine, ATL-derived factor (ADF), which has proved to
be important in redox regulation. At the end of 1981, I
moved from Kyoto to Kumamoto, which is located in the
middle of Kyushu. Our studies advanced remarkably
there, due mainly to the efforts of excellent young co-
workers including Drs. Kazunari Yamaguchi, Toshio Hat-
tori, and Masao Matsuoka, who are now independently
working in Tokyo, Sendai and Kyoto, respectively.
Development of virology
This discovery of ATL ushered in some dramatic develop-
ments in oncology, virology and, unexpectedly, neurology
and other fields of medicine. When we reported a series of
13 patients with ATL in 1976 on the occasion of the 16th
International Congress of Hematology in Kyoto, it was
stated that 'attempt to elucidate leukemogenesis in this
disease should be directed towards exploring the genetic
background and a possible viral involvement'. HTLV
(human T-cell leukemia virus), the pathogen of ATL, was
first reported by Dr. Robert C. Gallo and his co-workers in
Bethesda in 1980 and 1981. They isolated HTLV from cul-
tured cells taken from a patient with an aggressive variant
of mycosis fungoides and another with Sezary syndrome.
Although both patients were said to have cutaneous T-cell
lymphoma, they had some unusual features which, in ret-
rospect, linked them to the clinical entity now called ATL.
In Japan, co-culturing of ATL cells with umbilical cord
lymphocytes was first done successfully by Dr. Isao Miy-
oshi's group in Okayama, who obtained the cell line MT-
1. Dr. Yorio Hinuma and his co-workers in Kyoto demon-
strated that ATL patients have antibodies against pre-
sumed viral antigens on MT-1 cells by indirect
immunofluorescence method. Subsequently, a retrovirus
was isolated and called ATLV (adult T-cell leukemia
virus). Since Dr. Mitsuaki Yoshida and his group in Tokyo
showed that HTLV and ATLV are, in fact, identical, the
term HTLV-1 (human T-cell lymphotropic virus type 1)
has been commonly used.
Furthermore, the following observations have been suc-
cessively reported to support the etiologic association of
HTLV-1.
1. All patients with ATL have antibodies against HTLV-1.
2. The areas of high incidence of ATL patients correspond
closely with those of high incidence of HTLV-1 carriers.
3. HTLV-1 immortalizes human T cells in vitro.
4. Monoclonal integration of HTLV-1 proviral DNA was
demonstrated in ATL cells.
Thus, HTLV-1 is the first retrovirus directly associated with
human malignancy.
Diagnosis and classification of ATL
The diagnostic criteria for HTLV-1 associated ATL have
been defined as follows:
1. Presence of morphologically proven lymphoid malig-
nancy with T-cell surface antigens (These abnormal T lym-
phocytes include typical ATL cells and the small and
mature T lymphocytes with incised or lobulated nuclei
that are characteristic of chronic or smoldering type).
2. Presence of antibodies to HTLV-1 in the sera.
3. Demonstration of monoclonal integration of HTLV-1
provirus by Southern blot method.
Virological study led us to classify the patients with ATL
into four clinical subtypes according to the clinical fea-
tures: acute, chronic, smoldering, and lymphoma. The
acute type is the prototypic ATL in which patients exhibit
increased number of ATL cells, frequent skin lesions, sys-
temic lymphadenopathy, and hepatosplenomegaly. Most
of these patients are resistant to chemotherapy and have a
poor prognosis. In chronic ATL, white blood cell count is
mildly increased, and skin lesions, lymphadenopathy,
and hepatosplenomegaly are sometimes exhibited. In the
past, chronic ATL was thought to be 'chronic T-lym-
phocytic leukemia'. Smoldering ATL is characterized by
the presence of a few ATL cells in the peripheral bloodPublish with BioMed Central    and   every 
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over a period of years. Frequent symptoms are skin or pul-
monary lesions. Chronic and smoldering ATL often
progress to acute ATL after a long period (crisis). Lym-
phoma-type ATL is characterized by prominent systemic
lymphadenopathy, with few abnormal cells in the periph-
eral blood. This type has been diagnosed as nonleukemic
malignant lymphoma. Later, the Lymphoma Study Group
in Japan proposed a practical diagnostic criteria for classi-
fying ATL into these four subtypes.
Epidemiology of ATL and HTLV-1
HTLV-1 is endemic in southwestern Japan, especially
Kyushu and Okinawa, in the Caribbean Islands, and in
Central Africa. It has been revealed that there are HTLV-1
carriers in South America, Papua New Guinea, the Solo-
mon Islands, South China, and other isolated popula-
tions in the world, including Ainus in Hokkaido and
Aborigines in Australia. These epidemiological studies
have been promoted by international collaborations, to
which Drs. William A. Blattner in Bethesda, Guy de The in
Paris, Kazuo Tajima in Nagoya, Shunro Sonoda in
Kagoshima, and many other epidemiologists have made
important contributions. Dr. Daniel Catovsky and his col-
leagues in London delineated the clinical features of ATL
patients originating in the Caribbean islands.
HTLV-1 related diseases
On the other hand, several diseases have been found to be
related to HTLV-1 infection. Drs. Antoinne Gessain and
Guy de The first reported the association of tropical spas-
tic paraparesis (TSP) and HTLV-1, and Dr. Mitsuhiro
Osame and his co-workers in Kagoshima studied features
of HTLV-1-associated myelopathy (HAM/TSP) in detail.
HTLV-1 uveitis was subsequently described by a study
group of ophthalmologists in Kyushu. HTLV-1 may also
be associated with bronchopneumonitis, arthritis, poly-
myositis and other inflammatory conditions. Moreover, it
was noted that an immunodeficiency state may be
induced by HTLV-1 infection.
Prevention and treatment
In Japan, HTLV-1 carriers have been estimated to be 1.2
million, and more than 700 cases of ATL have been diag-
nosed each year. Majority of HTLV-1 transmission occurs
via one of three routes, all of which require the passage of
virus-infected cells. HTLV-1 carrier mothers transmit the
virus to newborns mainly through breast milk. Dr. Shigeo
Hino and his group in Nagasaki conducted intensive
fieldwork regarding the mother-to-infant infection. Car-
rier mothers in Japan have been instructed to refrain from
breastfeeding or modify the feeding procedures to prevent
HTLV-1 infection. There is convincing evidence that
HTLV-1 can be transmitted from individual to individual
by sexual contact, especially males to females, and also
through blood transfusions. All blood donated at the Red
Cross Blood Centers in Japan has been subjected to HTLV-
1 antibody testing beginning in November 1986.
Treatment of ATL is the most difficult task. Dr. Masanori
Shimoyama in Tokyo has organized a multicenter study
group for the chemotherapy of ATL. Many other trials
have been reported: deoxycoformycin, α -interferon com-
bined with azidothymidine, and so on. The use of human-
ized monoclonal antibodies against the interleukin-2
receptor has been championed by Dr. Waldmann's group.
More recently, successful allogeneic bone marrow trans-
plantation for patients with ATL has been reported from
many institutions.
Addendum
Before my retirement from Kumamoto University in
1996, I edited a book titled "Adult T-cell Leukaemia" [3].
Many of the above-mentioned investigators contributed
chapters to this book. I also would like to add that Dr.
Matsuoka and I wrote a chapter on ATL in a textbook of
leukemia [4]. It may be pertinent here to commemorate
the establishment of the International Retrovirology Asso-
ciation, which was announced on the occasion of the 5th
International Conference of Human Retrovirology held in
Kumamoto on May 11–13, 1992.
A companion article by Robert C. Gallo recollects the
events surrounding the discovery of the first human retro-
virus, HTLV-I [5].
References
1. Takatsuki K, Uchiyama T, Sagawa K, Yodoi J: Adult T cell leukemia
in Japan. In Topics in Hematology Edited by: Seno S, Takaku F, Irino S.
Amsterdam, Excerpta Medica; 1977:73-77. 
2. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H: Adult T-cell
leukemia: Clinical and hematologic features of 16 cases. Blood
1977, 50:481-492.
3. Takatsuki K, ed: Adult T-cell Leukaemia. Oxford, Oxford Univer-
sity Press; 1994. 
4. Matsuoka M, Takatsuki K: Adult T-Cell Leukemia. 7th edition.
Edited by: Henderson ES, Lister TA, Greaves MF. Leukemia, Philadel-
phia, Saunders; 2002:705-712. 
5. Gallo RC: The discovery of the first human retrovirus: HTLV-
1 and HTLV-2. Retrovirology 2005, 2:17.